SUBSCRIBE
SUBSCRIBE
News   Drug Development

Intercytex Limited Starts Skin Graft Substitute Trial

February 19, 2007 | 
1 min read

LONDON (SHARECAST) - Intercytex enjoyed gains today as the cell therapy outfit focused on skin and hair regeneration said it has started a Phase I study to evaluate the safety and tolerability of skin graft substitute ICX-SKN.

Clinical research Phase I Europe
MORE ON THIS TOPIC
Pictured: Entrance to Pfizer's office in Belgium
Breast cancer
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Dollar banknote cut into pieces on a yellow background
Gene therapy
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
2D illustration showing scientists' hands editing a DNA strand
Gene editing
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Modern collage with human heart and hands stock illustration
Cardiovascular disease
Deep Dive: Cardiovascular Disease Back in the Spotlight
March 10, 2025
 · 
2 min read
 · 
Heather McKenzie